• Increases blood pressure in septic or other distributive shock.

Contraindicated in:

• None.

Use Cautiously in:

• OB: Use only if potential maternal benefit outweighs potential fetal risk
• Lactation: Safety not established
• Pedi: Safety and effectiveness in children not established.

CV: thromboembolic events, peripheral ischemia, tachycardia.

Endo: hyperglycemia.

Hemat: thrombocytopenia.

Neuro: delirium.
Misc: fungal infection.

Drug-Drug:

• Concurrent use with ACE inhibitors may ↑ vasopressor effects.
• Concurrent use with angiotensin receptor blockers may ↓ vasopressor effects.

• Solution for IV infusion (must be diluted): 2.5 mg/mL;

• IV (Adults): 20 ng/kg/min continuous infusion; may be titrated every 5 min of up to 15 ng/kg/min to achieve or maintain target mean arterial pressure. Do not exceed dose of 80 ng/kg/min during first 3 hr. During maintenance therapy, do not exceed dose of 40 ng/kg/min. Once shock has adequately improved, titrate down by 15 ng/kg/min every 5–15 min based on mean arterial pressure.

Giapreza

• Causes vasoconstriction and release of aldosterone, which lead to an increase in blood pressure.

• Increase in mean arterial pressure.

Therapeutic Classification: vasopressors

Pharmacologic Classification: vasopressors

Absorption: IV administration results in complete bioavailability.

Distribution: Unknown.

Metabolism/Excretion: Metabolized by aminopeptidase A and angiotensin converting enzyme 2 to angiotensin-(2-8) [angiotensin III] and angiotensin-(1-7), respectively in plasma, erythrocytes and many major organs.

Half-life: <1 min.

(increase in mean arterial pressure)

• Educate patient on purpose of angiotensin II.
• Advise female patient to notify health care profession if pregnant.

an-jee-oh-TEN-sin too